Prostatitis/seminal vesiculitis

Known as: Prostatitis/Samenblasenentzuendung, Prostatitis/vesiculitis seminalis, Prostatite/vesiculite seminal 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Multidrug-resistant gram-negative bacterial (MDR-GNB) infections of the prostate are an increasing problem worldwide… (More)
  • table 1
  • figure 1
Is this relevant?
2011
2011
BACKGROUND Prostatitis is a poorly understood disease and increasing evidence suggests inflammation is involved in other… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
OBJECTIVES To investigate clinical outcomes, bacterial virulence factors, and antimicrobial resistance in E. coli from young men… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2009
2009
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 1. Chronic Prostatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 1.1 Category I: Acute Bacterial Prostatitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 1.2 Cat gory II: Chronic Bacterial Prostatitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 1.3 Category III: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) . . . . . . . . . . . . . . . . . . . 74 1.4 Category IV: Asymptomatic Inflammatory Prostatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 1.5 Presentation of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 1.6 Epidemiology of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 1.7 Pathophysiology of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 1.8 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 2. Treatment of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.1 Surgical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.2 Pelvic Floor Biofeedback . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.3 Antimicrobials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.4 a-Adrenergic Receptor Antagonists (a-Blockers). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 2.5 Combination Therapy with a-Blockers and Fluoroquinolones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 2.6 Anti-Inflammatory Agents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 2.7 5a-Reductase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 2.8 Glycosaminoglycans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 2.9 Phytotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 2.10 Others . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 2.11 Role of the Pharmacist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 3. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Abstract TheNational Institutes of Health (NIH) has redefined prostatitis into four distinct entities. Category I is acute bacterial prostatitis. It is an acute prostatic infection with a uropathogen, often with systemic symptoms of fever, chills and hypotension. The treatment hinges on antimicrobials and drainage of the bladder because the inflamed prostate may block urinary flow. Category II prostatitis is called chronic bacterial prostatitis. It is characterized by recurrent episodes of documented urinary tract infections with the same uropathogen and causes pelvic pain, urinary symptoms and ejaculatory pain. It is diagnosed by means of localization cultures that are 90% accurate in localizing the source of recurrent infections within the lower urinary tract. Asymptomatic inflammatory prostatitis comprises NIH category IV. This entity is, by definition, asymptomatic and is often diagnosed incidentally THERAPY IN PRACTICE Drugs 2009; 69 (1): 71-84 0012-6667/09/0001-0071/$55.55/0TheNational Institutes of Health (NIH) has redefined prostatitis into four distinct entities. Category I is acute bacterial prostatitis. It is an acute prostatic infection with a uropathogen, often with systemic symptoms of fever, chills and hypotension. The treatment hinges on antimicrobials and drainage of the bladder because the inflamed prostate may block urinary flow. Category II prostatitis is called chronic bacterial prostatitis. It is characterized by recurrent episodes of documented urinary tract infections with the same uropathogen and causes pelvic pain, urinary symptoms and ejaculatory pain. It is diagnosed by means of localization cultures that are 90% accurate in localizing the source of recurrent infections within the lower urinary tract. Asymptomatic inflammatory prostatitis comprises NIH category IV. This entity is, by definition, asymptomatic and is often diagnosed incidentally THERAPY IN PRACTICE Drugs 2009; 69 (1): 71-84 0012-6667/09/0001-0071/$55.55/0 a 2009 Adis Data Information BV. All rights reserved. 
  • table I
  • figure 1
  • figure 2
  • table II
  • figure 3
Is this relevant?
Review
2008
Review
2008
Prostatitis, a histologic diagnosis, has evolved over the years to describe a clinical syndrome that was believed to be… (More)
Is this relevant?
2007
2007
OBJECTIVES An animal model for nonbacterial prostatitis in rats was developed with the use of intraprostatic injection of… (More)
Is this relevant?
2004
2004
OBJECTIVES To determine the risk factors for the self-reported history of prostatitis and to determine whether a self-reported… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE We examine whether leukocytes and bacteria correlate with symptom severity in men with chronic prostatitis/chronic pelvic… (More)
Is this relevant?
2002
2002
Although bacterial prostatitis is a common diagnosis, well documented infections of the prostate are uncommon. Culture studies of… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
OBJECTIVES An association between prostatitis and male infertility has been suspected, yet is poorly understood. Prostatitis is… (More)
  • table I
Is this relevant?